rs121918447

Variant summary

Our verdict is Uncertain significance. Variant got 5 ACMG points: 5P and 0B. PS3PM2_Supporting

This summary comes from the ClinGen Evidence Repository: The NM_000212.2(ITGB3):c.2332T>C (p.Ser778Pro) missense variant has been reported in at one Glanzmann thrombasthenia patient (PMID:1438206). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). The receptor function of αIIbβ3, measured by functional flow cytometry, in CHO cells transiently co-transfected with the Ser778Pro variant β3 and wild type αIIb showed minimal binding to ligand mimetic antibody PAC-1 indicating that this variant impacts protein function (PMID:8080992; PS3). In summary, this variant meets the criteria to be classified as uncertain significance for autosomal recessive Glanzmann Thrombasthenia based on the ACMG/AMP criteria applied, as specified by the ClinGen PD VCEP: PS3, PM2_supporitng. (VCEP specifications version 2; date of approval 11/04/2021). LINK:https://erepo.genome.network/evrepo/ui/classification/CA123230/MONDO:0100326/011

Frequency

Genomes: not found (cov: 32)

Consequence

ITGB3
ENST00000559488.7 missense

Scores

9
7
2

Clinical Significance

Uncertain significance reviewed by expert panel P:1U:1

Conservation

PhyloP100: 5.56
Variant links:
Genes affected
ITGB3 (HGNC:6156): (integrin subunit beta 3) The ITGB3 protein product is the integrin beta chain beta 3. Integrins are integral cell-surface proteins composed of an alpha chain and a beta chain. A given chain may combine with multiple partners resulting in different integrins. Integrin beta 3 is found along with the alpha IIb chain in platelets. Integrins are known to participate in cell adhesion as well as cell-surface mediated signalling. [provided by RefSeq, Jul 2008]
EFCAB13-DT (HGNC:55338): (EFCAB13 divergent transcript)

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Uncertain_significance. Variant got 5 ACMG points.

PS3
For more information check the summary or visit ClinGen Evidence Repository.
PM2
For more information check the summary or visit ClinGen Evidence Repository.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE Protein UniProt
ITGB3NM_000212.3 linkuse as main transcriptc.2332T>C p.Ser778Pro missense_variant 15/15 ENST00000559488.7 NP_000203.2
EFCAB13-DTNR_110880.1 linkuse as main transcriptn.363-6387A>G intron_variant, non_coding_transcript_variant
EFCAB13-DTNR_110881.1 linkuse as main transcriptn.227-6387A>G intron_variant, non_coding_transcript_variant

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Protein Appris UniProt
ITGB3ENST00000559488.7 linkuse as main transcriptc.2332T>C p.Ser778Pro missense_variant 15/151 NM_000212.3 ENSP00000452786 P1P05106-1
EFCAB13-DTENST00000575039.1 linkuse as main transcriptn.227-6387A>G intron_variant, non_coding_transcript_variant 5

Frequencies

GnomAD3 genomes
Cov.:
32
GnomAD4 exome
Cov.:
30
GnomAD4 genome
Cov.:
32

ClinVar

Significance: Uncertain significance
Submissions summary: Pathogenic:1Uncertain:1
Revision: reviewed by expert panel
LINK: link

Submissions by phenotype

Glanzmann thrombasthenia 2 Pathogenic:1
Pathogenic, no assertion criteria providedliterature onlyOMIMNov 01, 1992- -
Glanzmann thrombasthenia Uncertain:1
Uncertain significance, reviewed by expert panelcurationClinGen Platelet Disorders Variant Curation Expert Panel, ClinGenNov 04, 2021The NM_000212.2(ITGB3):c.2332T>C (p.Ser778Pro) missense variant has been reported in at one Glanzmann thrombasthenia patient (PMID: 1438206). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). The receptor function of αIIbβ3, measured by functional flow cytometry, in CHO cells transiently co-transfected with the Ser778Pro variant β3 and wild type αIIb showed minimal binding to ligand mimetic antibody PAC-1 indicating that this variant impacts protein function (PMID: 8080992; PS3). In summary, this variant meets the criteria to be classified as uncertain significance for autosomal recessive Glanzmann Thrombasthenia based on the ACMG/AMP criteria applied, as specified by the ClinGen PD VCEP: PS3, PM2_supporitng. (VCEP specifications version 2; date of approval 11/04/2021). -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
0.97
BayesDel_addAF
Pathogenic
0.41
D
BayesDel_noAF
Pathogenic
0.35
CADD
Pathogenic
26
DANN
Uncertain
1.0
DEOGEN2
Pathogenic
0.92
D
Eigen
Pathogenic
0.86
Eigen_PC
Pathogenic
0.84
FATHMM_MKL
Pathogenic
0.99
D
LIST_S2
Uncertain
0.94
D
M_CAP
Uncertain
0.14
D
MetaRNN
Pathogenic
0.97
D
MetaSVM
Uncertain
0.0014
D
MutationAssessor
Uncertain
2.4
M
MutationTaster
Benign
1.0
A;A;A
PrimateAI
Pathogenic
0.81
D
PROVEAN
Uncertain
-3.0
D
Sift
Benign
0.031
D
Sift4G
Uncertain
0.032
D
Polyphen
1.0
D
Vest4
0.89
MutPred
0.89
Loss of MoRF binding (P = 0.0739);
MVP
0.97
MPC
1.4
ClinPred
0.95
D
GERP RS
6.0
Varity_R
0.95
gMVP
0.97

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.040
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs121918447; hg19: chr17-45387535; API